Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study)

References

• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–11.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250–60.
   PubMed Web of Science ®Google Scholar
• Van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63:72–9.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219–25.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617–25.
   PubMed Web of Science ®Google Scholar
• Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012;35:562–7.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014;20:1368–74.
   PubMed Web of Science ®Google Scholar
• Mortensen C, Caspersen S, Christensen NL, Svenningsen L, Thorsgaard N, Christensen LA, et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis 2011;5:28–33.
   PubMed Web of Science ®Google Scholar
• Monterubbianesi R, Arati A, Armuzzi A, Daperno M, Biancone L, Cappello M, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. J Crohns Colitis 2014;8:852–8.
   PubMed Web of Science ®Google Scholar
• Teisner AS, Ainsworth MA, Brynskov J. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol 2010;45:1457–63.
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Fris-Liby J, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, et al. Managing ambulatory ulcerative colitis patients with infliximab: A long-term follow-up study in primary gastroenterology centers. Eur J Intern Med 2014;25:757–61.
   PubMed Web of Science ®Google Scholar
• Filippi J, Allen PB, Hébuteme X, Peyrin-Birulet L. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011;12:1440–7.
   PubMed Web of Science ®Google Scholar
• Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol 2013;28:1829–33.
   PubMed Web of Science ®Google Scholar
• Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, Hébuterne X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013;37:998–1004.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–201.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013;19:1065–72.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, et al. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. J Crohns Colitis 2014;8:981–91.
   PubMed Web of Science ®Google Scholar
• Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, et al. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012;47:359–65.
   PubMed Web of Science ®Google Scholar
• Protic M, Seibold F, Scheopfer A, Radojicic Z, Juillerat P, Bojic D, et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427–37.
   PubMed Web of Science ®Google Scholar
• Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011;106:771–7.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Tanida S, Mizoshita T, Ozeki K, Ebi M, Shimura T, et al. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. Eur J Gastroenterol Hepatol 2013;25:714–18.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther 2012;35:275–83.
   PubMed Web of Science ®Google Scholar
• Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107:179–94.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 2010;25:886–91.
   PubMed Web of Science ®Google Scholar
• Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;25:1055–60.
   PubMed Web of Science ®Google Scholar
• Blumenstein I, Hermann E, Filmann N, Zosel C, Tacke W, Bock H, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 2011;5:203–10.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, Bultman E, Vogelaar L, Bouziane C, Kuipers EJ, van der Woude CJ. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol 2012;18:6967–73.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392–400.
   PubMed Web of Science ®Google Scholar
• Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177–85.
   PubMed Web of Science ®Google Scholar